SCHEMBL3237145

SCHEMBL3237145

COc1cc(Cl)ccc1C(=O)NC(c1ccccc1)C1(N(C)C)CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 1/20 0.43
GPR27 Q9NS67 1/20 0.43
ALDH1A1 P00352 6/20 0.43
HPGD P15428 1/20 0.43
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
F10 P00742 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.39
KCNMA1 Q12791 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238721 0.88 ALDH1A1 (0.46) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL3244636 0.87 THRB (0.43) MEN1KMT2AL3MBTL1MAPTHIF1A
SCHEMBL3244199 0.87 MEN1 (0.49) GPR27ALDH1A1FLT1FLT4KDR
SCHEMBL3238270 0.87 ALDH1A1 (0.57) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL3239983 0.86 UTS2R (0.42) GPR27ALDH1A1FLT1FLT4KDR
SCHEMBL3237602 0.85 GPR139 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2SLC6A9
SCHEMBL3237485 0.84 SLC6A9 (0.48) ALDH1A1L3MBTL1NPSR1SMN1; SMN2SLC6A9
SCHEMBL3237710 0.83 ALDH1A1 (0.42) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL4357362 0.83 PLK1 (0.50) ALDH1A1HPGDMEN1KMT2ANPSR1
SCHEMBL3238379 0.82 ACLY (0.45) ALDH1A1HPGDMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 AVPR2 322/4885GPR27 549/4885ALDH1A1 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.